| __timestamp | Blueprint Medicines Corporation | Bristol-Myers Squibb Company |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 5699000000 |
| Thursday, January 1, 2015 | 14456000 | 5001000000 |
| Friday, January 1, 2016 | 19218000 | 5002000000 |
| Sunday, January 1, 2017 | 27986000 | 4849000000 |
| Monday, January 1, 2018 | 47928000 | 4551000000 |
| Tuesday, January 1, 2019 | 96388000 | 4871000000 |
| Wednesday, January 1, 2020 | 157743000 | 7661000000 |
| Friday, January 1, 2021 | 195293000 | 7690000000 |
| Saturday, January 1, 2022 | 237374000 | 7814000000 |
| Sunday, January 1, 2023 | 295141000 | 7772000000 |
| Monday, January 1, 2024 | 359272000 | 8414000000 |
Unlocking the unknown
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. Bristol-Myers Squibb Company (BMY) and Blueprint Medicines Corporation (BPMC) offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. Over the past decade, BMY has consistently outspent BPMC, with SG&A expenses peaking at approximately $7.8 billion in 2022, a staggering 2,500% more than BPMC's $295 million in the same year. This disparity highlights BMY's expansive operational scale compared to BPMC's more focused approach. However, BPMC's SG&A expenses have grown nearly 3,600% since 2014, reflecting its aggressive growth strategy. As the pharmaceutical industry continues to innovate, these spending patterns provide insights into how companies allocate resources to maintain competitive edges and drive future growth.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Bristol-Myers Squibb Company
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Grifols, S.A.
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Bristol-Myers Squibb Company and Wave Life Sciences Ltd.
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Blueprint Medicines Corporation
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Axsome Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Alpine Immune Sciences, Inc.
Blueprint Medicines Corporation and Ultragenyx Pharmaceutical Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Blueprint Medicines Corporation vs Ligand Pharmaceuticals Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Dynavax Technologies Corporation